Breast cancer multigene test
Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Sports ~ Technology ~ Health ~ Features
Twitter ~ Facebook
Home / Technology News / 2010 / January 2010 / January 12, 2010
Breast cancer multigene test may help patients avoid chemo
RSS / Print / Comments

University of Michigan

Husbands better at resolving marital conflicts: Study

Lying really does create desire to clean 'dirty' body part

How you fight with your spouse can predict the fate of your marriage

More on University of Michigan

Breast cancer

Sysmex Announces Establishment of Overseas Subsidiary in Spain to Expand Life Science Business

Breast cancer multigene test may help patients avoid chemo

Mangoes may protect against breast, colon cancer

More on Breast cancer

Technology News

Study to find whether leptin helps type 1 diabetic patients
To determine whether adding the hormone leptin to standard insulin therapy might help rein in the tumultuous blood-sugar levels of people with type 1 (insulin-dependent) diabetes, a clinical trial at UT Southwestern Medical Center is being carried out. ANI

Why deaf have 'super vision'
Researchers have found reasons for the enhanced abilities in the remaining senses of deaf people. ANI

Tsunami risk higher than expected in LA, other major cities
A new study has revealed that the risk of destructive tsunamis is in places such as Kingston, Istanbul, and Los Angeles. ANI

Breast cancer multigene test may help patients avoid chemo

A new study shows that a 21-gene test of a patients breast cancer tumour may change doctor and patient treatment decisions, including the need for chemotherapy.


Washington, Jan 12 : A new study shows that a 21-gene test of a patient's breast cancer tumour may change doctor and patient treatment decisions, including the need for chemotherapy.

The test, Oncotype DX, is made by Genomic Health Inc. It examines 21 genes from a tumour sample to determine how active they are.

A test score between 0 and 100 predicts how likely the cancer is to recur. For women with low scores, chemotherapy is not recommended.

More than 120,000 breast cancer patients have undergone the test since it became commercially available in 2004.

The test is intended for patients who have a type of breast cancer, called estrogen receptor-positive, which has not spread to the lymph nodes. About 100,000 such cases are diagnosed each year.

"The trend in oncology is towards personalized medicine. We likely will see more tests similar to this one in the future," said Loyola University Health System Medical oncologist and study's lead author Dr. Shelly Lo.

The findings are based on study, which included 89 breast cancer patients who received the gene test.

They were treated by 17 medical oncologists at Loyola, University of Michigan, University of California at Davis and Edward Hospital in Naperville, Il.

Doctors changed treatment decisions for 28 patients. In 20 of these cases, they changed their decision from hormone therapy plus chemotherapy to hormone therapy alone. 24 patients changed their treatment decisions, including nine who dropped chemotherapy.

"This is the first study to show that results from this test simultaneously impact decisions by physicians as well as patients," Lo said.

The study has been published in the Journal of Clinical Oncology.

ANI

Link to this page

Suggested pages for your additional reading
AndhraNews.net on Facebook






© 2000-2017 AndhraNews.net. All Rights Reserved and are of their respective owners.
Disclaimer, Terms of Service & Privacy Policy | Contact Us